 PENNINGTON, N.J. and SAN DIEGO, March 25, 2021 PRNewswire -- OncoSec Medical Incorporated NASDAQ:ONCS the Company or OncoSec, a biotechnology company focused on cytokine-based intratumoral cancer immunotherapies, today announced it will sponsor a key opinion leader KOL webinar to be held by LifeSci Advisors discussing the anti-PD-1 checkpoint refractory metastatic melanoma landscape and the impact of the results from ILLUMINATE-301 on Wednesday, March 31, 2021 at 12:00 p.m. 